Capital Fund Management (CFM)’s Maravai LifeSciences MRVI Stock Holding History

Capital Fund Management (CFM)’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-111,051	Closed	-$1.56M	–	1814
2023 Q1	$1.56M	Sell	111,051 -180,266	-62%	-$2.59M	0.01%	1141
2022 Q4	$4.17M	Buy	291,317 +119,500	+70%	+$1.88M	0.03%	678
2022 Q3	$4.39M	Buy	171,817 +96,887	+129%	+$2.43M	0.03%	591
2022 Q2	$2.13M	Buy	74,930 +45,433	+154%	+$1.44M	0.02%	799
2022 Q1	$1.04M	Buy	+29,497	New	+$989K	0.01%	1142

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Capital Fund Management (CFM)'s MRVI Position: Q2 2023 in Review

Capital Fund Management (CFM) sold out of Maravai LifeSciences (MRVI) in Q2 2023, closing a stake of 111,051 shares — an estimated $1.56M sold.

Capital Fund Management (CFM) first reported a position in MRVI in Q1 2022 and held it in 5 quarters. The position peaked at $4.39M in Q3 2022. 221 funds tracked by Wall St. Rank hold MRVI as of Q2 2023.

Capital Fund Management (CFM) reported no remaining Maravai LifeSciences position as of Q2 2023 after selling out during the quarter.
Capital Fund Management (CFM) sold 111,051 Maravai LifeSciences shares in Q2 2023, an estimated $1.56M.
Capital Fund Management (CFM) first reported a position in Maravai LifeSciences in Q1 2022 and held it in 5 quarters.
Capital Fund Management (CFM)'s Maravai LifeSciences position peaked at $4.39M in Q3 2022.
221 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2023.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2023, filed 14 Aug 2023.